5:50 PM
 | 
Feb 09, 2015
 |  BC Extra  |  Top Story

Achillion climbs on ACH-3102 data

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) gained $0.84 to $11.66 on Monday after it said 100% of HCV genotype 1 patients receiving ACH-3102 plus Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) achieved an SVR12 after six weeks of treatment in a Phase II trial. The trial evaluated...

Read the full 228 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >